Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Map Pharmaceuticals, a developer of new therapies for the treatment of asthma and chronic obstructive pulmonary disease, has appointed Scott Ward to its board of directors.
Subscribe to our email newsletter
Mr Ward is currently senior vice president and president of the cardiovascular sector at Medtronic. In this role, Mr Ward is responsible for all worldwide operations of the coronary, peripheral, endovascular, structural heart disease and revascularization and surgical therapies businesses.
Timothy Nelson, president and CEO of Map Pharmaceuticals, said: “The addition of Scott’s product development and commercialization experience to the board of directors will benefit Map Pharmaceuticals as we continue to advance our two lead drug candidates for pediatric asthma and acute migraine through Phase III clinical trials and potential commercialization.”